Onsdag 28 Oktober | 18:10:49 Europe / Stockholm

All ägardata du vill ha finns i Holdings!

AroCell - Q4’21 review

2022-02-28 10:00:00

Redeye returns with a more detailed take on the Q4 report with some estimate changes, primarily for the two coming years. We reiterate our fair value range, suggesting a hefty upside from today’s share price levels, but emphasize the market volatility and an overhang from guarantors’ commitments from the rights issue.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/